Prediction of thrombocytopenia and bleeding risk in patients with von Willebrand disease type 2B was studied by performing the quantification of the von Willebrand factor from plasma samples in its GPIb-α binding conformation using the AU/VWFa-11 nanobody. Here, VWF is linked to Thrombocytopenia.